Science Explorer Back to mapMap

Most cited papers from Ono Pharmaceutical (United States)

What are the most cited papers from Ono Pharmaceutical (United States)?

The most cited paper from Ono Pharmaceutical (United States) is "Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease" (Brent R. Stockwell et al., 2017), with 7,867 citations. Next come "Applications of machine learning in drug discovery and development" (3,274) and "Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding" (1,317).

Showing 50 of 60 papers. Every paper with more than 272 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease Brent R. Stockwell et al. · Cell Open access Oct 2017 7,867
2 Applications of machine learning in drug discovery and development Jessica J. Vamathevan, Dominic A. Clark, Paul Czodrowski et al. · Nature Reviews Drug Discovery ReviewOpen access 11 Apr 2019 3,274
3 Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding Gabriela P. Saborı́o, Bruno Permanne, Claudio A. Soto · Nature 14 Jun 2001 1,317
4 Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial Howard L. Kaufman, Jeffery Scott Russell, Omid Hamid et al. · The Lancet Oncology Open access 7 Sep 2016 1,235
5 An empirical correlation of second virial coefficients Constantine Tsonopoulos · AIChE Journal Mar 1974 971
6 Ultrasonic Atomization of Liquids Robert J. Lang · The Journal of the Acoustical Society of America 1962 903
7 Dual specificity phosphatases: a gene family for control of MAP kinase function Montserrat Camps, ANTON NICHOLS, Steve Arkinstall · The FASEB Journal 2000 818
8 The Bcl-2 Protein Family Bruno E. Antonsson, Jean‐Claude Martinou · Experimental Cell Research Open access Apr 2000 792
9 Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines Amanda E. I. Proudfoot, Tracy M. Handel, Zoë Johnson et al. · Proceedings of the National Academy of Sciences Open access 5 Feb 2003 788
10 The minimum information about a proteomics experiment (MIAPE) Chris F. Taylor et al. · Nature Biotechnology Open access Aug 2007 782
11 Probability Model for Estimating Three-Phase Relative Permeability Howard Stone · Journal of Petroleum Technology Open access Feb 1970 776
12 Chemokine receptors: multifaceted therapeutic targets Amanda E. I. Proudfoot · Nature reviews. Immunology ReviewOpen access Feb 2002 770
13 Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study Luc Yves Dirix, István Takács, Guy Jérusalem et al. · Breast Cancer Research and Treatment Open access 23 Oct 2017 764
14 A continuum theory for granular materials M.A. Goodman, Stephen C. Cowin · Archive for Rational Mechanics and Analysis 1972 735
15 Bax Is Present as a High Molecular Weight Oligomer/Complex in the Mitochondrial Membrane of Apoptotic Cells Bruno E. Antonsson, Sylvie Montessuit, Belén G. Sánchez et al. · Journal of Biological Chemistry Open access Apr 2001 676
16 Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria Bruno E. Antonsson, Sylvie Montessuit, Sandra Lauper et al. · Biochemical Journal Open access 10 Jan 2000 630
17 Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial Manish R. Patel, John Allan Ellerton, Jeffrey R. Infante et al. · The Lancet Oncology Open access 5 Dec 2017 591
18 Computation of modal solutions in layered, elastic media at high frequencies John W. Dunkin · Bulletin of the Seismological Society of America Apr 1965 561
19 Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 Yu Jeong Bang, Eduardo Yañez Ruiz, Eric Van Cutsem et al. · Annals of Oncology Open access 23 Jul 2018 508
20 Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial Daniel D. Mikol, Frederik Barkhof, Peter Chang et al. · The Lancet Neurology 12 Sep 2008 487
21 Supported ?bimetallic cluster? catalysts John H. Sinfelt · Journal of Catalysis May 1973 484
22 Expression and Characterization of the Chemokine Receptors CCR2 and CCR5 in Mice Matthias Mack, Josef Cihak, Christopher Simonis et al. · The Journal of Immunology Apr 2001 474
23 Predicting Two-Phase Pressure Drops in Vertical Pipe J. Orkiszewski · Journal of Petroleum Technology Open access Jun 1967 454
24 Response Factors for Gas Chromatographic Analyses Werner Dietz · Journal of Chromatographic Science Feb 1967 450
25 Priorities in Parkinson's disease research Wassilios G. Meissner, Mark A. Frasier, Thomas Gasser et al. · Nature Reviews Drug Discovery Review 29 Apr 2011 435
26 A Branch-Bound Algorithm for Plant Location M. A. Efroymson, T. L. Ray · Operations Research Jun 1966 426
27 LAMINA, LAMINASET, BED AND BEDSET Charles V. Campbell · Sedimentology Feb 1967 420
28 Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study Fabrice Barlési, Johan Vansteenkiste, David Robert Spigel et al. · The Lancet Oncology 24 Sep 2018 400
29 Study of intra- and interlaboratory variability in the results of rabbit eye and skin irritation tests Carrol S. Weil, Robert A. Scala · Toxicology and Applied Pharmacology Jun 1971 391
30 Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma Sandra P. D’Angelo, Jeffery Scott Russell, Célèste Lebbé et al. · JAMA Oncology Open access 22 Mar 2018 376
31 Antagonism of RANTES Receptors Reduces Atherosclerotic Plaque Formation in Mice Niels R. Veillard, Brenda Renata Kwak, Graziano Pelli et al. · Circulation Research Open access Dec 2003 375
32 Therapies for rare diseases: therapeutic modalities, progress and challenges ahead Erik Tambuyzer, Benjamin Vandendriessche, Christopher P. Austin et al. · Nature Reviews Drug Discovery Review 13 Dec 2019 367
33 Cellular imaging in drug discovery Paul Lang, Karen Yeow, Anthony Charles Nichols et al. · Nature Reviews Drug Discovery Review 31 Mar 2006 354
34 Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis Marc C. Hochberg, Ali Guermazi, Hans Guehring et al. · JAMA Open access 8 Oct 2019 353
35 Longitudinal Acoustical Vibrations of Finite Polymethylene Chains Robert F. Schaufele, Takehiko Shimanouchi · The Journal of Chemical Physics Nov 1967 349
36 Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study Gavin Giovannoni, Per Soelberg Sørensen, Stuart D. Cook et al. · Multiple Sclerosis Journal Open access 5 Sep 2017 344
37 Protein misfolding and disease; protein refolding and therapy Claudio A. Soto · FEBS Letters 8 Jun 2001 340
38 Specificity in Catalytic Hydrogenolysis by Metals John H. Sinfelt · Advances in catalysis Book chapter 1973 340
39 Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial Ludwig Kappos, Hans‐Peter Hartung, Mark Steven Freedman et al. · The Lancet Neurology 6 Mar 2014 337
40 Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial Howard L. Kaufman, Jeffery Scott Russell, Omid Hamid et al. · Journal for ImmunoTherapy of Cancer Open access 16 Jan 2018 335
41 Bax and other pro-apoptotic Bcl-2 family "killer-proteins" and their victim the mitochondrion Bruno E. Antonsson · Cell and Tissue Research 30 Oct 2001 334
42 Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function Young‐Hee Lee et al. · Cell Research Open access 7 Jul 2017 332
43 Considerations in the development of circulating tumor cell technology for clinical use David Parkinson et al. · Journal of Translational Medicine Open access 2 Jul 2012 327
44 Large-Scale Assessment of Binding Free Energy Calculations in Active Drug Discovery Projects Christina Schindler et al. · Journal of Chemical Information and Modeling 19 Aug 2020 322
45 Evidence for the Existence of a Minimum of Two Phases of Ordered Water in Skeletal Muscle Carlton F. Hazlewood, Buford Lee Nichols, Nugent F. Chamberlain · Nature May 1969 321
46 Shale Alteration by Water Adsorption Martin E. Chenevert · Journal of Petroleum Technology Open access Sep 1970 314
47 Temperature Distribution in a Circulating Drilling Fluid L.R. Raymond · Journal of Petroleum Technology Mar 1969 312
48 Effect of pH on Interfacial Films and Stability of Crude Oil-Water Emulsions J.E. Strassner · Journal of Petroleum Technology Mar 1968 309
49 Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial Christopher Ryan Heery, Geraldine O’Sullivan Coyne, Ravi Amrit Madan et al. · The Lancet Oncology Open access 31 Mar 2017 303
50 Solid phase DNA amplification: characterisation of primer attachment and amplification mechanisms Céline Adessi · Nucleic Acids Research Open access 15 Oct 2000 300

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.